Targeting CDH17 in cancer: when blocking the ligand beats blocking the receptor?

Cadherin-17 (CDH17) has been implicated as pro-tumorigenic for many years but mechanisms have been unclear. A Spanish team have generated antibodies to an RGD-motif in CDH17 that inhibits integrin α2β1 binding to CDH17 and thereby inhibits integrin activation, tumorigenesis and metastasis. These reagents may have therapeutic potential.

from Cancer via ola Kala on Inoreader http://ift.tt/2yfC0CR
via IFTTT